Positive data from study of Valiant Thoracic Stent Graft System for aortic aneurysms- Medtronic

Medtronic has announced favourable five-year data in the VALOR II Study, demonstrating the durability of the Valiant Thoracic Stent Graft System, an innovative and minimally invasive treatment for patients with thoracic aortic aneurysms (TAA). Key VALOR II five-year follow-up findings include 94.8% freedom from aneurysm related mortality, 1.3% rupture rate, 6.9% required secondary procedures, 0.6% (1/160) conversion to open surgery rate, 89.3% of patients had stable or decreased aneurysm size and no patients reported migration or loss of integrity. The data, results of five-year patient follow-up, were presented at the 42nd Annual Meeting of the New England Society for Vascular Surgery.

VALOR II is a prospective, single-arm study that involved 160 patients at 24 US medical centres. It was designed to evaluate the safety and effectiveness of the Valiant Thoracic Stent Graft System for thoracic endovascular aortic repair (TEVAR) of aneurysms in the descending thoracic aorta. The Valiant Thoracic Stent Graft System is indicated for the endovascular repair of all lesions of the descending thoracic aorta in patients having appropriate anatomy, including: iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories, non-aneurysmal aortic diameter in the range of 18-42 mm and non-aneurysmal aortic proximal and distal neck lengths of at least 20 mm.